ADAMTS13 and thrombotic thrombocytopenic purpura: In addition, our results cannot be applied to patients with acquired TTP without detectable anti‐ADAMTS13 antibodies at baseline (also termed uTTP) However, these patients may achieve ADAMTS13 activity > 20% faster than those with detectable autoantibodies [20, 21], and therefore may not require prolonged caplacizumab treatment.